Five stocks stand out heading into Friday, September 18, 2026, each carrying a bullish rating change issued on Thursday, September 17. The Federal Open Market Committee held the federal funds target range at 3.50% to 3.75% at its July 29 meeting, and the CME Group FedWatch tool still prices roughly an 80% probability that policy rates hold steady through the balance of 2026.
The five ideas below span intermodal freight, packaged food, blood-management devices, equipment rental, and precision-timing semiconductors. Editorial notes only, not investment advice.
J.B. Hunt Transport Services (JBHT) – Citizens Turns Bullish on Intermodal Freight
Intermodal and dedicated-fleet trucking operator J.B. Hunt Transport Services was upgraded from Market Perform to Outperform on Thursday by Citizens. The thesis focuses on intermodal volumes reaccelerating as trans-Pacific rail-conversion trends firm, dedicated contract-services segment producing durable margin expansion through fleet-utilization gains, and pricing power holding on contract renewals as truckload capacity remains constrained.
Shares traded near $238.56 during Thursday's session, up about 0.77%, giving J.B. Hunt a market capitalization near $22 billion. The 52-week range of $130.12 to $299.76 shows the stock trading in the upper half of the year's range after a strong summer recovery. The trailing price-to-earnings multiple sits at 33.81, and the dividend yield sits near 1%.
Consensus reads buy on the broader panel. Twenty sell-side firms cover the name with 12 bullish, seven neutral, and one bearish. The average price target of $293.95 implies roughly 23% upside from Thursday's level, and the panel high sits at $370.
Risks: The panel is not uniformly aligned. UBS's Thomas Wadewitz maintained Neutral at $264 on September 17 (target trimmed from $291), and Baird's Daniel Moore trimmed to $290 from $320 the same day while maintaining Outperform. Intermodal-volume trajectory, dedicated-fleet margin durability, and truckload-competition dynamics all remain factors to monitor.
Kraft Heinz (KHC) – RBC Initiates Contrarian Bullish
Packaged-food giant Kraft Heinz drew a fresh Outperform initiation on Thursday from RBC Capital. The thesis focuses on planned corporate simplification (a potential split of the Kraft and Heinz portfolios) unlocking sum-of-the-parts value, category-specific pricing normalization stabilizing volumes, and productivity-savings program funding renewed advertising investment behind core brands.
Shares traded near $24.89 during Thursday's session, up about 0.63%, giving Kraft Heinz a market capitalization near $30 billion. The 52-week range of $21.04 to $28.09 shows the stock trading in the middle of the year's range. The trailing price-to-earnings multiple reads negative at negative 8.70 on a depressed earnings base tied to impairment charges, and the dividend yield sits near 6%.
Consensus reads sell on the broader panel, making RBC's initiation a clear outlier. Fourteen sell-side firms cover the name with zero bullish, 10 neutral, and four bearish. The average price target of $23.64 sits below Thursday's level, and the panel high sits at $28.
Risks: The panel remains cautious in aggregate. Evercore ISI Group's David Palmer maintained In-Line at $23 on September 14 (target trimmed from $24), and TD Cowen's Robert Moskow maintained Hold at $22 on August 6. Portfolio-split execution, packaged-food volume trajectory, and private-label competitive dynamics all remain factors to monitor.
Haemonetics (HAE) – Citigroup Turns Bullish on Blood-Management Franchise
Blood-management medical-device maker Haemonetics was upgraded from Neutral to Buy on Thursday by Citigroup analyst Joanne Wuensch, who raised her price target to $123 from $92. The thesis focuses on plasma-collection franchise growth stabilizing as commercial-plasma-collector customer relationships reset, hospital segment (interventional-technology portfolio) gaining traction on Vascade and Vivasure product ramps, and margin expansion holding as manufacturing productivity gains compound.
Shares traded near $108.87 during Thursday's session, up about 2.48% on the upgrade catalyst, giving Haemonetics a market capitalization near $5 billion. The 52-week range of $47.32 to $109.83 shows the stock trading near multi-year highs. The trailing price-to-earnings multiple sits at 53.32.
Consensus reads strong buy on the broader panel. Nine sell-side firms cover the name with eight bullish and one neutral. The average price target of $103.22 sits roughly in line with Thursday's level, and Raymond James' Andrew Cooper sits at the high at $125 with an Outperform rating on September 3.
Risks: Even a strong-buy consensus carries dispersion. Citigroup's own prior Neutral stance held from February at $75 (later $64 and $70), and the plasma-collection segment remains exposed to commercial-collector customer concentration. Interventional-technology adoption pace, plasma-franchise stabilization, and margin-expansion trends all remain factors to monitor.
Sunbelt Rentals (SUNB) – Goldman Sachs Turns Bullish on Equipment Rental
Construction and industrial equipment-rental leader Sunbelt Rentals was upgraded from Neutral to Buy on Thursday by Goldman Sachs analyst Suhasini Varanasi, who raised her price target to $93 from $78. The thesis focuses on North American non-residential construction activity reaccelerating as reshoring and infrastructure spending firm, specialty rental categories (climate, power, trench) contributing higher-margin growth alongside general-tool rental, and free-cash-flow conversion expanding as fleet capital-expenditure intensity normalizes.
Shares traded near $73.67 during Thursday's session, up about 1.82% on the upgrade catalyst, giving Sunbelt Rentals a market capitalization near $30 billion. The 52-week range of $61.03 to $86.68 shows the stock trading in the middle of the year's range. The trailing price-to-earnings multiple sits at 22.23, and the dividend yield sits near 1%.
Consensus reads buy on the broader panel. Seven sell-side firms cover the name with four bullish, one neutral, and two bearish. The average price target of $84.71 implies roughly 15% upside from Thursday's level, and Goldman's own $93 target ties the panel high.
Risks: The panel is far from uniform. JPMorgan's Tami Zakaria maintained Underweight at $79 on September 10 (target raised from $71 but still bearish), and B of A Securities' Arnaud Lehmann maintained Underperform at $71 the same day. Non-residential construction trajectory, specialty-rental mix growth, and fleet capital-expenditure discipline all remain factors to monitor.
SiTime (SITM) – Morgan Stanley Initiates Bullish on Precision Timing
Precision-timing semiconductor maker SiTime drew a fresh Overweight initiation on Thursday from Morgan Stanley. The thesis focuses on MEMS-based timing devices displacing legacy quartz oscillators across AI-datacenter, networking, and automotive applications, customer content growth on next-generation compute platforms lifting average selling prices, and gross-margin structure benefiting from fabless manufacturing scale.
Shares traded near $597.25 during Thursday's session, up about 8.81% on the initiation catalyst, giving SiTime a market capitalization near $16 billion. The 52-week range of $243.68 to $901.81 shows the stock trading in the middle of the year's range. The trailing price-to-earnings multiple sits well above 1,000 on a still-scaling earnings base.
Consensus reads strong buy on the broader panel. Five sell-side firms cover the name with all five in the bullish camp. The average price target of $672 implies roughly 13% upside from Thursday's level, and Needham's N. Quinn Bolton sits at the panel high at $900.
Risks: Even a fully bullish panel carries dispersion. The low price target of $270 sits well below Thursday's level, reflecting caution from Raymond James' Melissa Fairbanks at $270 (Outperform, August 29, 2025). MEMS-timing customer-content growth pace, AI-datacenter demand durability, and legacy-quartz competitive response all remain factors to monitor.
Found this helpful? Share it with others.